Does Second-Line Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Confer a Survival Benefit? By Matthew StengerPosted: 12/19/2019 8:07:00 AM Last Updated: 12/20/2019 1:45:32 PM Richard S. Finn, MD As reported in the Journal of Clinical Oncology…
Rates of early-onset gastrointestinal cancers, beyond just colorectal cancer, are rising among people younger than age 50, according to experts from Dana-Farber Cancer Institute.
In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in…
“Steroids were the biggest predictor of why certain immunotherapies may not be effective, even when considering multiple other factors such as stage and progression of…
In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes…
A study that included nearly 2.5 million children born in Sweden found the risk of ALL was 21% higher in children born by planned cesarean…
A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may…
Over the past 20 years, increased understanding of the biological mechanism of disease has led to improved treatment options for all malignancies. Within each disease…
Childhood cancer survivors had a lower risk of contracting COVID-19 but were 58% more likely to develop severe disease if they did become infected, according…
In a phase II trial reported in The Lancet Oncology, Elimova et al evaluated the efficacy and safety of zanidatamab plus chemotherapy in the first-line…
A study led by researchers at the American Cancer Society has found that after the introduction of immune checkpoint inhibitors in 2011, there was a…
